HERZLIYA, Israel, and CALGARY, AB — The Mexican patent office has issued a notice of allowance for Innocan Pharma Corporation’s patent application covering its proprietary topical pain-relief technology.
The patent covers a groundbreaking formulation comprising the unique blending of cannabidiol with minerals to deliver fast-acting, targeted pain relief. Clinical studies have demonstrated noticeable pain reduction within 20 minutes of application.
The Mexican allowance adds to previously granted counterpart patents in the United States, Russia, and Ukraine, and complements a growing portfolio of pending applications across various global jurisdictions. This development positions Innocan for early and strategic access to Latin American markets.
“We are very excited about the patent approval of our topical pain relief technology in Mexico,” said Iris Bincovich, Chief Executive Officer.
Innocan Pharma intends to continue expanding its intellectual property portfolio in other key territories worldwide, reinforcing its leadership in cannabidiol-based wellness innovation.
About Innocan Pharma
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary.
